Body and Mind Inc.

CNSX:BAMM Stock Report

Market Cap: CA$1.8m

Body and Mind Valuation

Is BAMM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BAMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BAMM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BAMM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BAMM?

Key metric: As BAMM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BAMM. This is calculated by dividing BAMM's market cap by their current revenue.
What is BAMM's PS Ratio?
PS Ratio0.06x
SalesUS$22.98m
Market CapUS$1.30m

Price to Sales Ratio vs Peers

How does BAMM's PS Ratio compare to its peers?

The above table shows the PS ratio for BAMM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
AREV AREV Life Sciences Global
15.5xn/aCA$2.9m
TILT TILT Holdings
0.01x-1.5%CA$3.9m
THC THC Biomed Intl
1.5xn/aCA$3.3m
HMPG Hempshire Group
7.8xn/aCA$2.1m
BAMM Body and Mind
0.06xn/aCA$1.3m

Price-To-Sales vs Peers: BAMM is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does BAMM's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.0.8x10.8%
BAMM Body and Mind
 0.06xn/aUS$1.30m
AYR.A Ayr Wellness
0.2x2.5%US$79.88m
IAN iAnthus Capital Holdings
0.1xn/aUS$47.73m
BAMM 0.1xIndustry Avg. 0.8xNo. of Companies25PS012345+
26 CompaniesEstimated GrowthMarket Cap
Industry Avg.0.8x53.6%
BAMM Body and Mind
 0.06xn/aUS$1.30m
No more companies

Price-To-Sales vs Industry: BAMM is good value based on its Price-To-Sales Ratio (0.1x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is BAMM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BAMM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.06x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BAMM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

7D

29.4%

1Y

-35.8%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$1.98

7D

-17.2%

1Y

-65.9%

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

7D

9.4%

1Y

69.0%